BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

614 related articles for article (PubMed ID: 16219680)

  • 21. Sulfated glycans and elevated temperature stimulate PrP(Sc)-dependent cell-free formation of protease-resistant prion protein.
    Wong C; Xiong LW; Horiuchi M; Raymond L; Wehrly K; Chesebro B; Caughey B
    EMBO J; 2001 Feb; 20(3):377-86. PubMed ID: 11157745
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Mechanisms of prion transmission].
    Sakaguchi S
    Nihon Rinsho; 2007 Aug; 65(8):1391-5. PubMed ID: 17695274
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anti-PrP antibodies block PrPSc replication in prion-infected cell cultures by accelerating PrPC degradation.
    Perrier V; Solassol J; Crozet C; Frobert Y; Mourton-Gilles C; Grassi J; Lehmann S
    J Neurochem; 2004 Apr; 89(2):454-63. PubMed ID: 15056288
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Preventing misfolding of the prion protein by trimethylamine N-oxide.
    Bennion BJ; DeMarco ML; Daggett V
    Biochemistry; 2004 Oct; 43(41):12955-63. PubMed ID: 15476389
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lithium induces clearance of protease resistant prion protein in prion-infected cells by induction of autophagy.
    Heiseke A; Aguib Y; Riemer C; Baier M; Schätzl HM
    J Neurochem; 2009 Apr; 109(1):25-34. PubMed ID: 19183256
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Recognition of lumenal prion protein aggregates by post-ER quality control mechanisms is mediated by the preoctarepeat region of PrP.
    Gilch S; Nunziante M; Ertmer A; Wopfner F; Laszlo L; Schätzl HM
    Traffic; 2004 Apr; 5(4):300-13. PubMed ID: 15030571
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Curative properties of antibodies against prion protein: a comparative in vitro study of monovalent fragments and divalent antibodies.
    Alexandrenne C; Hanoux V; Dkhissi F; Boquet D; Couraud JY; Wijkhuisen A
    J Neuroimmunol; 2009 Apr; 209(1-2):50-6. PubMed ID: 19232746
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Specific inhibition of pathological prion protein accumulation by small interfering RNAs.
    Daude N; Marella M; Chabry J
    J Cell Sci; 2003 Jul; 116(Pt 13):2775-9. PubMed ID: 12759373
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunolocalisation of PrPSc in scrapie-infected N2a mouse neuroblastoma cells by light and electron microscopy.
    Veith NM; Plattner H; Stuermer CA; Schulz-Schaeffer WJ; Bürkle A
    Eur J Cell Biol; 2009 Jan; 88(1):45-63. PubMed ID: 18834644
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The prion protein requires cholesterol for cell surface localization.
    Gilch S; Kehler C; Schätzl HM
    Mol Cell Neurosci; 2006 Feb; 31(2):346-53. PubMed ID: 16278084
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prion and doppel proteins bind to granule cells of the cerebellum.
    Legname G; Nelken P; Guan Z; Kanyo ZF; DeArmond SJ; Prusiner SB
    Proc Natl Acad Sci U S A; 2002 Dec; 99(25):16285-90. PubMed ID: 12446843
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Binding of neural cell adhesion molecules (N-CAMs) to the cellular prion protein.
    Schmitt-Ulms G; Legname G; Baldwin MA; Ball HL; Bradon N; Bosque PJ; Crossin KL; Edelman GM; DeArmond SJ; Cohen FE; Prusiner SB
    J Mol Biol; 2001 Dec; 314(5):1209-25. PubMed ID: 11743735
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Involvement of glypican-1 autoprocessing in scrapie infection.
    Löfgren K; Cheng F; Fransson LA; Bedecs K; Mani K
    Eur J Neurosci; 2008 Sep; 28(5):964-72. PubMed ID: 18717736
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development of oligomeric prion-protein aggregates in a mouse model of prion disease.
    Sasaki K; Minaki H; Iwaki T
    J Pathol; 2009 Sep; 219(1):123-30. PubMed ID: 19479969
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Motif-grafted antibodies containing the replicative interface of cellular PrP are specific for PrPSc.
    Moroncini G; Kanu N; Solforosi L; Abalos G; Telling GC; Head M; Ironside J; Brockes JP; Burton DR; Williamson RA
    Proc Natl Acad Sci U S A; 2004 Jul; 101(28):10404-9. PubMed ID: 15240877
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anti-prion drug mPPIg5 inhibits PrP(C) conversion to PrP(Sc).
    McCarthy JM; Franke M; Resenberger UK; Waldron S; Simpson JC; Tatzelt J; Appelhans D; Rogers MS
    PLoS One; 2013; 8(1):e55282. PubMed ID: 23383136
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Specific binding of normal prion protein to the scrapie form via a localized domain initiates its conversion to the protease-resistant state.
    Horiuchi M; Caughey B
    EMBO J; 1999 Jun; 18(12):3193-203. PubMed ID: 10369660
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Semiautomated cell-free conversion of prion protein: applications for high-throughput screening of potential antiprion drugs.
    Breydo L; Bocharova OV; Baskakov IV
    Anal Biochem; 2005 Apr; 339(1):165-73. PubMed ID: 15766724
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Truncated PrP(c) in mammalian brain: interspecies variation and location in membrane rafts.
    Laffont-Proust I; Hässig R; Haïk S; Simon S; Grassi J; Fonta C; Faucheux BA; Moya KL
    Biol Chem; 2006 Mar; 387(3):297-300. PubMed ID: 16542151
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Differential solubility of prions is associated in manifold phenotypes.
    Kuczius T; Karch H; Groschup MH
    Mol Cell Neurosci; 2009 Nov; 42(3):226-33. PubMed ID: 19607920
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.